COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

OCT Reference Database

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01986478
Recruitment Status : Completed
First Posted : November 18, 2013
Last Update Posted : March 27, 2014
Information provided by (Responsible Party):
Topcon Medical Systems, Inc.

Brief Summary:
To collect data for a reference database.

Condition or disease

Detailed Description:
Collection of multiple subjects to create a reference database.

Layout table for study information
Study Type : Observational
Actual Enrollment : 389 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Topcon 3D OCT-1 Maestro and 3D OCT-2000 Optical Coherence Tomography Systems: Reference Database Study
Study Start Date : October 2013
Actual Primary Completion Date : March 2014
Actual Study Completion Date : March 2014

Normal results from clinical exam and free of ocular pathology

Primary Outcome Measures :
  1. Retinal Thickness [ Time Frame: Day 1 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects that are Normal

Inclusion Criteria:

  1. Subjects 18 years of age or older on the date of informed consent
  2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  3. Subjects presenting at the site with normal eyes (eyes without pathology)
  4. IOP ≤ 21 mmHg bilaterally
  5. BCVA 20/40 or better (each eye)
  6. Both eyes must be free of eye disease

Exclusion Criteria:

  1. Subjects unable to tolerate ophthalmic imaging
  2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images
  3. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT 'Outside Normal Limits' and/or PSD < 5%
  4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses > 33% or false positives > 25%, or false negatives > 25%
  5. Presence of any ocular pathology except for cataract
  6. Previous ocular surgery or laser treatment, other than uncomplicated refractive procedure or cataract surgery, performed within six months prior to study scanning
  7. Narrow angle
  8. History of leukemia, dementia or multiple sclerosis
  9. Concomitant use of hydroxychloroquine and chloroquine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01986478

Layout table for location information
United States, Arizona
Horizon Eye Specialist & Laser Center
Scottsdale, Arizona, United States, 85054
United States, California
Valley Eyecare Center
Livermore, California, United States, 94550
Keck School of Medicine
Los Angeles, California, United States, 90033
Western University of Health Sciences
Pomona, California, United States, 91716
United States, New York
Stat University of New York College of Optometry
New York, New York, United States, 10036
Sponsors and Collaborators
Topcon Medical Systems, Inc.
Layout table for investigator information
Principal Investigator: Michael Sinai, PhD Senior Manager Product Planning Group
Layout table for additonal information
Responsible Party: Topcon Medical Systems, Inc. Identifier: NCT01986478    
Other Study ID Numbers: DC-001
First Posted: November 18, 2013    Key Record Dates
Last Update Posted: March 27, 2014
Last Verified: March 2014